Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Ophthalmology. Retina·2026
Same author

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.

Ophthalmology and therapy·2026
Same author

Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmology Research: Insights and Recommendations from a Swiss Multicentric Study.

Klinische Monatsblatter fur Augenheilkunde·2026
Same author

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Ophthalmology science·2026
Same author

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Ophthalmology and therapy·2026
Same author

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Ophthalmology and therapy·2026

Related Experiment Videos

Outcome indicators for vitrectomy in Terson syndrome.

Justus G Garweg1, Fritz Koerner

  • 1Swiss Eye Institute, Bern, Switzerland. justus.garweg@swiss-eye-institute.com

Acta Ophthalmologica
|June 10, 2008
PubMed
Summary

Early vitrectomy for Terson syndrome improves visual outcomes. Younger patients and those operated on within 90 days of vitreous hemorrhage experience better results, though late complications like retinal detachment can occur.

Related Experiment Videos

Area of Science:

  • Ophthalmology
  • Retina Surgery
  • Vitreoretinal Diseases

Background:

  • Terson syndrome, characterized by vitreous hemorrhage, lacks consensus on optimal surgical timing.
  • Vitrectomy is a common treatment, but factors influencing outcomes require further investigation.

Purpose of the Study:

  • To evaluate factors affecting functional outcomes and complication rates after vitrectomy for Terson syndrome.
  • To identify optimal timing and patient characteristics for improved surgical results.

Main Methods:

  • Retrospective analysis of consecutive case series of patients undergoing vitrectomy for Terson syndrome.
  • Data collected from 1975 to 2005, including patient demographics, visual acuity, and surgical outcomes.

Main Results:

  • Significant visual acuity improvement observed post-vitrectomy (0.07 to 0.72).
  • Patients operated within 90 days and those younger than 45 years achieved better final visual acuity (P=0.03 and P=0.006, respectively).
  • Late complications, including retinal detachment, occurred in a small percentage of patients.

Conclusions:

  • Vitrectomy for Terson syndrome leads to rapid and sustained visual recovery in most patients.
  • Shorter latency to surgery and younger patient age are key predictors of favorable outcomes.
  • While generally safe, potential for late complications necessitates continued monitoring.